Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

The correlation between patient characteristics and expectations of benefit from Phase I clinical trials.

Weinfurt KP, Castel LD, Li Y, Sulmasy DP, Balshem AM, Benson AB 3rd, Burnett CB, Gaskin DJ, Marshall JL, Slater EF, Schulman KA, Meropol NJ.

Cancer. 2003 Jul 1;98(1):166-75.

2.

[Informed consent in phase I trial].

Shimada Y.

Gan To Kagaku Ryoho. 1996 Jan;23(2):226-30. Review. Japanese.

PMID:
8611051
3.

INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.

[No authors listed]

Drugs R D. 2007;8(3):176-87. Review.

PMID:
17472413
4.

Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.

[No authors listed]

Drugs R D. 2005;6(3):178-85. Review.

PMID:
15869322
5.
6.

[Reasons why patients do or do not participate in clinical trials; a systemic review of the literature].

Nievaard MA, de Vos R, de Haes JC, Levi M.

Ned Tijdschr Geneeskd. 2004 Jan 24;148(4):186-90. Review. Dutch.

PMID:
14974312
7.

Patient-reported outcomes in overactive bladder: the influence of perception of condition and expectation for treatment benefit.

Marschall-Kehrel D, Roberts RG, Brubaker L.

Urology. 2006 Aug;68(2 Suppl):29-37. Review.

PMID:
16908338
8.

Decision making for cancer clinical trial participation: a systematic review.

Biedrzycki BA.

Oncol Nurs Forum. 2010 Nov;37(6):E387-99. doi: 10.1188/10.ONF.E387-E399. Review.

PMID:
21059572
9.

[Getting informed consent in clinical trials on Japanese cancer patients].

Sasako M.

Gan To Kagaku Ryoho. 1996 Jan;23(2):146-50. Review. Japanese.

PMID:
8611041
10.

Informed consent in complementary and alternative medicine: current status and future needs.

Monaco GP, Smith G.

Semin Oncol. 2002 Dec;29(6):601-8. Review.

PMID:
12516044
11.

[Perceptions of patients and physicians involved in clinical trials: an overview of the literature].

Henry A, Corvaisier S, Blanc S, Berthezene F, Borson-Chazot F, Broussolle E, Ryvlin P, Touboul P.

Therapie. 2006 Sep-Oct;61(5):425-37. Review. French.

PMID:
17243272
12.

Decision-Making Process Related to Participation in Phase I Clinical Trials: A Nonsystematic Review of the Existing Evidence.

Gorini A, Mazzocco K, Pravettoni G.

Public Health Genomics. 2015;18(6):359-65. doi: 10.1159/000441559. Epub 2015 Nov 4. Review.

PMID:
26529420
13.

[How to share results of clinical trials with study participants?].

Sarradon-Eck A, Mancini J, Genre D, Sakoyan J, Desclaux A, Julian-Reynier C.

Med Sci (Paris). 2012 Mar;28 Spec No 1:33-6. doi: 10.1051/medsci/2012281s109. Epub 2012 Apr 9. Review. French.

14.

The complexity of consenting to clinical research in phase I pediatric cancer studies.

Schechter T, Grant R.

Paediatr Drugs. 2015 Feb;17(1):77-81. doi: 10.1007/s40272-014-0113-1. Review.

PMID:
25573671
15.

Communication and informed consent in phase 1 trials: a review of the literature from January 2005 to July 2009.

Jenkins VA, Anderson JL, Fallowfield LJ.

Support Care Cancer. 2010 Sep;18(9):1115-21. doi: 10.1007/s00520-010-0836-7. Epub 2010 Mar 4. Review.

PMID:
20204418
16.

Understanding cognitive processes behind acceptance or refusal of phase I trials.

Pravettoni G, Mazzocco K, Gorini A, Curigliano G.

Crit Rev Oncol Hematol. 2016 Apr;100:69-73. doi: 10.1016/j.critrevonc.2016.01.023. Epub 2016 Jan 23. Review.

PMID:
26852078
17.

Patient information in phase 1 trials: A systematic review.

Gad KT, Lassen U, Mau-Søerensen M, Høybye MT, Johansen C.

Psychooncology. 2017 Sep 27. doi: 10.1002/pon.4559. [Epub ahead of print] Review.

PMID:
28960785
18.

Risks and benefits of phase 1 clinical trial participation.

Mahipal A, Nguyen D.

Cancer Control. 2014 Jul;21(3):193-9. Review.

19.

Defining and managing expectations for early immunotherapy cancer trials.

Kieber-Emmons T, Pennisi A, Lane A, Siegel E, Cannon M, Monzavi-Karbassi B, Makhoul I.

Rev Recent Clin Trials. 2015;10(1):47-60. Review.

PMID:
25723736

Supplemental Content

Support Center